The GLP-1 Boom and a Lingering Question
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications that have transformed the treatment of type 2 diabetes and, more recently, obesity. By mimicking a natural hormone, drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) slow
down digestion, regulate blood sugar, and signal a feeling of fullness to the brain. Their effectiveness has led to a surge in use. Yet, a persistent puzzle has emerged from real-world data: a large percentage of patients, estimated between 50% to over 60% in some studies, stop taking these medications within the first year. This high discontinuation rate is a major concern, as the benefits of these drugs, including weight loss and improved cardiovascular health, are typically lost after treatment ceases.
Beyond the Usual Suspects
For a long time, the conversation around why patients stop GLP-1 therapy has centered on three main factors: cost, access, and side effects. The high price tag, often running over a thousand dollars a month without insurance, is a significant barrier for many. On top of that, the well-documented gastrointestinal side effects—including nausea, vomiting, constipation, and diarrhea—can be difficult for some patients to tolerate, especially in the beginning. These issues are very real and account for a large portion of discontinuations. However, this explanation might not tell the whole story. A recent observational study introduces a more nuanced perspective, suggesting a complex link between stopping the medication and the patient's broader health status.
A New Study Points to Acute Illness
A recent study published in The Lancet Regional Health Europe on November 9, 2026, analyzed data from thousands of patients with type 2 diabetes who were prescribed a GLP-1 medication. It found that patients who stopped the treatment had a significantly higher risk of major cardiovascular events like heart attack and stroke compared to those who continued. While this highlights the drugs' protective benefits, the authors noted something crucial: the dramatic increase in risk is unlikely to be explained only by the withdrawal of the drug. They suggest that the act of stopping treatment may be a sign of a patient's worsening health. In other words, a sudden or severe illness might be the very thing that prompts a patient to discontinue their GLP-1 therapy.
Why This Distinction Is Critical
Distinguishing between discontinuing because of the drug's known, manageable side effects and stopping because of a separate, acute illness is vital. GLP-1 drugs intentionally slow stomach emptying, which causes common side effects like nausea. However, an acute case of gastroenteritis or another serious illness might produce similar symptoms, leading both patient and doctor to mistakenly blame the medication. As the study authors suggest, a patient becoming ill might lead them to stop their medication, but it is the illness itself, not just the absence of the drug, that elevates their health risks. This reframes the issue from simple 'treatment failure' to a more complex clinical event. Understanding this can help doctors better support their patients. Instead of just advising them to stop the medication, they can investigate for an underlying illness that needs treatment, potentially allowing the patient to safely continue the beneficial GLP-1 therapy later.
















